Under the normalization of alliance procurement, a large number of drugs and consumables will be reduced in price

[Pharmaceutical Network Industry News] In recent years, alliance procurement has long been the norm in the industry, but it is worth noting that cross-provincial alliance procurement has become more and more frequent this year
.

Recently, the Inner Mongolia Autonomous Region Pharmaceutical Procurement Center issued the "Notice on Publicizing the Results of the Proposed Selection of the Third Batch of Centralized Procurement of Drugs in the "Eight Provinces and Two Regions" Inter-Provincial Alliance"
.

According to sorting out, a total of 17 varieties and 26 product specifications have been included in this proposed selection
.

There are 25 companies to be selected, including Shandong Yijian, Harbin Sanlian, Chia Tai Pharmaceutical (Qingdao), North China Pharmaceutical Hebei Huamin, Shandong Luoxin, Hainan Huluwa,
etc.

Among the products to be selected this time, Piracetam injection (5ml: 1g) with a higher price drop, with a price limit of 49.
6 yuan, and a proposed price of 0.
98 yuan, with a planned drop of 98%; followed by acetyl half-half for inhalation Cystine solution (3ml: 0.
3g), the price limit is 9.
38 yuan, and the proposed price is 0.
9 yuan, with a planned decrease of 90.
4%; the price of ceftizoxime sodium for injection (0.
5g) is 32 yuan, and the proposed price is 32 yuan.
It is 3.
79 yuan, a planned drop of 88.
2%
.

 　　It is worth noting that the first batch of procurement of the eight provinces and two districts alliance started in January 2021, and three batches have been basically completed by March this year, with an amazing speed
.

In addition to the eight provinces and two districts, there are currently several inter-provincial alliances that are also carrying out centralized procurement, including the alliance of 14 provinces (districts, corps) such as Inner Mongolia, and the alliance of 10 provinces (districts, corps) such as Shaanxi
.

 　　Before this, the Beijing-Tianjin-Hebei "3+N" alliance organization also carried out the joint procurement of orthopaedic trauma medical consumables
.

The alliance procurement is carried out in the way of "volume linkage, two-way selection", which not only adheres to the integration of recruitment and procurement, and the link between volume and price, but also supports the diversity of clinical choices, respects the use habits of medical institutions, and ensures the continuity of clinical use
.

From the results, 20,026 products from 89 companies were selected, with an average price reduction of 83.
48%
.

 　　In this centralized procurement, the total amount of agreed procurement in the alliance area is 1,085,700 sets; the industry estimates that after the implementation of the centralized procurement results, the annual procurement amount of the alliance area can be saved by 5.
917 billion yuan; Tianjin is expected to save 139 million yuan in purchase amount per year
.

 　　In the same month, the Guangdong Provincial Drug Trading Center also issued the "Notice on Viewing Information about Guangdong Alliance Qingkailing and other Chinese patent medicines for centralized purchase and registration of products"
.

According to the notice, the members of the Guangdong Traditional Chinese Medicine Collective Procurement Alliance include Guangdong, Shanxi, Henan, Hainan, Ningxia, and Qinghai
.

 　　It is reported that this centralized purchase registration covers many common exclusive and non-exclusive Chinese patent medicine varieties, including: Qingkailing, Lanqin, Xingnaojing, Bailing, Shengmai, Fufang Danshen, Xuesaitong, Ginkgo biloba, Kanglaite, Lianhua Qingwen, Shenkang, Tanreqing, Xiyan are equal
.

With the arrival of the Centralized Procurement Alliance of Chinese Patent Medicines in 6 provinces, it is generally believed in the industry that a large number of pharmaceutical companies will face the test of price reduction
.

 　　The industry believes that, on the whole, inter-provincial alliance centralized procurement has gradually become the main force of volume procurement
.

In this context, the centralized procurement of drugs with volume will be significantly upgraded in 2022.
More super regional alliances and cross-regional alliances will successively test the waters to carry out volume procurement, and the pace of centralized procurement may be further accelerated
.

 　　Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.